RxDoctor Payments Data

Alyssa Kuprenas, MD

Internal Medicine · Concord, NCNPI 1063916468

Payments from drug & device makers

$890in general payments, 2019–2025

Across 45 payments — averaging $19.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$219
  • Novo Nordisk$156
  • Insulet Corporation$125
  • Pfizer$123
  • GSK$73
  • Boehringer Ingelheim$64
  • plus $130 from 5 others

What the payments were for

  • Food & beverage$890100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$890 in reported general payments places this provider in the 70th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$90,542
Medicare patients
197
Services billed
1,529

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide118$160,712
JardianceEmpagliflozin152$134,402
EliquisApixaban112$113,877
OzempicSemaglutide79$106,179
TrulicityDulaglutide52$51,015
Dupixent PenDupilumab11$43,090
XareltoRivaroxaban31$39,367
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$28,522
Tresiba Flextouch U-100Insulin Degludec26$21,137
Repatha SureclickEvolocumab21$19,337
MyrbetriqMirabegron14$16,516
LinzessLinaclotide15$13,089
JanuviaSitagliptin Phosphate18$11,025
SymbicortBudesonide/Formoterol Fumarate29$7,121
VascepaIcosapent Ethyl13$5,976

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$219$211,726170 claims
Boehringer IngelheimJardiance$64$134,402152 claims
PfizerEliquis$123$113,877112 claims
Novo NordiskOzempic$156$106,17979 claims
Johnson & JohnsonXarelto$32$39,36731 claims
GSKTrelegy Ellipta$73$28,52235 claims
MerckJanuvia$17$11,02518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Concord

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →